To investigate the role of IL-25 in intestinal tumorigenesis, Apc1322T/+ mice were treated with recombinant IL-25 (rIL-25) three times a week for eight weeks (Fig. 2A), which led to a substantial increase in tumor burden (Fig. 2B and fig. Here, IL25 is linked to neoplasm.